Suppr超能文献

针对α1和α2选择性拮抗剂哌唑嗪和育亨宾的抗体,作为α-肾上腺素能结合位点的探针。

Antibodies to the alpha 1- and alpha 2-selective antagonists prazosin and yohimbine as probes of the alpha-adrenergic binding sites.

作者信息

Graham R M, Hess H J, Haber E, Homcy C J

出版信息

Hypertension. 1982 May-Jun;4(3 Pt 2):183-7.

PMID:6279501
Abstract

Antibodies were raised against a newly synthesized analog (CP57,609) of the alpha 1-selective antagonist prazosin, and against the alpha 2-selective antagonist, yohimbine, by immunization of rabbits with antigens prepared by covalent linkage of these ligands to albumin. Competitive inhibition of [3H]prazosin binding to anti-CP57,609 antiserum by a variety of unlabeled ligands revealed a spectrum of antibody specificity, with alpha 1-selective agents competing more potently than alpha 2-selective ligands. In contrast, alpha 2-selective ligands competed more potently with the binding of [3H]yohimbine to the anti-yohimbine antiserum than alpha 1-selective agents. These respective antisera were subjected to affinity fractionation of a CP57,609- or yohimbine-Sepharose 4B resin. Fractions from the CP57,609 resin were eluted successively with phentolamine (10(-3)M), prazosin (10(-4)M), and guanidine (5M), and from the yohimbine resin with prazosin (10(-4)M), yohimbine (10(-4)M), and guanidine (5M). The binding profiles of these fractions differed, and in certain fractions the relative order of potency of adrenergic agents was almost identical to that observed with membrane alpha-adrenergic receptors. Moreover, using these eluted fractions as immunogens, antisera have been obtained which, in the initial bleeds, already possess antiidiotypic activity. These findings therefore suggest that affinity fractionation of antibodies raised against alpha 1- and alpha 2-selective antagonists may provide useful analogs for the further study of the ligand recognition properties of alpha-adrenergic receptors. Additionally, it is probable that antiidiotypic antisera will be developed which will recognize the alpha-adrenergic binding sites.

摘要

通过将这些配体与白蛋白共价连接制备抗原,对家兔进行免疫,从而产生了针对α1选择性拮抗剂哌唑嗪的新合成类似物(CP57,609)以及针对α2选择性拮抗剂育亨宾的抗体。多种未标记配体对[3H]哌唑嗪与抗CP57,609抗血清结合的竞争性抑制作用揭示了一系列抗体特异性,其中α1选择性药物比α2选择性配体竞争更有效。相反,α2选择性配体与[3H]育亨宾与抗育亨宾抗血清的结合竞争比α1选择性药物更有效。将这些相应的抗血清用CP57,609或育亨宾 - 琼脂糖4B树脂进行亲和分级分离。来自CP57,609树脂的级分依次用酚妥拉明(10^(-3)M)、哌唑嗪(10^(-4)M)和胍(5M)洗脱,来自育亨宾树脂的级分用哌唑嗪(10^(-4)M)、育亨宾(10^(-4)M)和胍(5M)洗脱。这些级分的结合图谱不同,并且在某些级分中,肾上腺素能药物的效价相对顺序与膜α - 肾上腺素能受体观察到的几乎相同。此外,使用这些洗脱级分作为免疫原,已获得抗血清,在最初的采血中,这些抗血清已经具有抗独特型活性。因此,这些发现表明,针对α1和α2选择性拮抗剂产生的抗体的亲和分级分离可能为进一步研究α - 肾上腺素能受体的配体识别特性提供有用的类似物。此外,很可能会开发出能够识别α - 肾上腺素能结合位点的抗独特型抗血清。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验